The Society for
Functional Precision Medicine

Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.


Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminars which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Lawrence BoiseOlli Kallioniemi

Our September seminar is Wednesday, September 9th, 2020 at 11:00 AM EST, featuring Lawrence Boise, PhD - Emory University, and Olli Kallioniemi - Karolinska Institute.

Zoom Information

URL:  https://dfci.zoom.us

Meeting ID: 936 9981 1786
Password: 351904

 Learn More   Register for Seminar


Recent News

August 17, 2020
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse.

READ MORE


July 15, 2020
Tumor Organoids for Functional Precision Oncology

Researchers are using patient-derived tumor organoids to match patients with optimal treatments - When most people think of precision cancer medicine, they think of genomics, with researchers trying to decipher complex gene interactions for the clinical benefit of patients. But according to Dr. Christopher Kemp, a cancer biologist at the Fred Hutchinson Cancer Research Center, that is a narrow view: “[Genomics] is important, but it’s not the whole puzzle by any stretch.”

READ MORE


June 29, 2020
Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD

Anthony Letai, PhD gives an overview of how BH3 profiling can be used to predict response to therapy. “There is an enormous amount of actionable information that can be obtained from taking the actual cancer cell you’re interested in and subjecting it to a relevant perturbation, that is, exposing it to the actual drugs,” he said. “We nearly completely overlook this in today’s precision medicine approaches, and I think there is enormous unrealized potential in this general approach.”

READ MORE


June 29, 2020
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors - Authored by Letai Lab member Patrick Bhola, PhD

“Cancer cells that are cultured for extended periods of time can undergo a variety of changes and may not be representative of the tumor cells that are actually in a mouse or human,” says study first author Patrick Bhola, PhD, of Dana-Farber. “The challenge has been to create a drug-screening technique that shrinks the gap between tumor cells in the body and the cells we do the screening on. The technique we’ve developed helps to accomplish that.” Read Dana Farber’s press release about HT-DBP technology for more information.

READ MORE


ALL NEWS